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Cardiac risk in HIV-infected patients C a r d i a c a b n o r m a l i t i e s i n h u m a n immunodeficiency syndrome have been reported for the first time in 1983 following the autopsy of a 24-years-old patient who had Kaposi sarcoma on the entire anterior cardiac wall . In autopsy studies, the prevalence of (1) cardiac abnormalities varies between 8-73%.
Antemortem, the cardiac dysfunction can be identified by clinical or paraclinical methods.
Cardiac involvement in HIV-infected patients is a negative prognostic factor, it affects the quality of life and the survival rate.
The pathophysiology of HIV cardiomyopathy is multifactorial. Metabolic disorders, chronic inflammation, coronary artery disease, myocarditis, cocaine use, antiretroviral toxicity, neoplasia and malnutrition are involved in heart disease in HIV-infected patients.
Coronary heart disease is a very important non-infectious complication in these patients. Risk factors for HIV-associated coronary heart disease are the same as in the general population, but these patients have HIV-specific risk factors like inflammation, i m m u n e a c t i v a t i o n a n d e n d o t h e l i a l dysfunction. 
i t o r s , t h e i n c i d e n c e o f
hypertriglyceridemia was 38.2% and hypercholesterolemia was 25% . Protease (2) inhibitors target the catalytic region of HIV-1 protease . This region is homologous with (3) regions of two human proteins that regulate lipid metabolism CRABP-1 (Cellular Retinoic Acid-Binding Protein Type 1) and LRP (Low Density Lipoprotein Receptor-Related Protein) . Therefore, PI inhibit the action of (4) CRABP-1 and bind to LRP, which leads to hyperlipidemia. By linking to CRBP-1, protease inhibitors interrupt the metabolism of retinoic acid and reduce PPAR-γ activity (peroxisome proliferator-activated gamma r e c e p t o r ) , r e s u l t i n g i n a d i p o c y t e differentiation but also in apoptosis of these c e l l s . T h e s e p h e n o m e n a l e a d t o hyperlipidemia by reducing the peripheral lipid storage and increasing their release into the blood . These patients had high plasma (5) triglyceride levels which may correlate with the viral load. 
Protease inhibitors can direct downregulation of the glucose transporter (GLUT-4), the major transporter of glucose into fat cells and cardiac and skeletal muscle .
Another mechanism by which protease inhibitors (except for atazanavir) affect insulin sensitivity include direct effects on IRS-1 phosphorylation (substrate receptor-1 insulin) and on subsequent glucose uptake in adipocytes . Also, chronic inflammation has (9) its role in insulin resistance. Lipodystrophy can lead to the destruction of pancreatic beta cells .
Some retrospective studies demonstrate that the risk of cardiovascular disease was grater in HIV-infected patients on antiretroviral therapy than those without antiretroviral therapy . Drugs like indinavir, lopinavir-
ritonavir, didanosine and abacvir are associated with a high cardiovascular risk . 
HIV-related risk factors
Inflammation is thought to be a major determinant in the pathogenesis of both diabetes mellitus and atherosclerosis.
However, the key inflammatory molecules involved in atheroma and diabetes mellitus in HIV individuals on HA ART are poorly understood.
Epicardial and thoracic periaortic fat deposits have been associated to high levels of hsCRP, i n s u l i n r e s i s t a n c e a n d untreated HIV infection, the net effect of s t a r t i n g a n t i r e t r o v i r a l t h e r a p y o n cardiovascular disease risk is unknown as it may increase or decrease the overall risk . 
In a large meta-analysis from the ART era General Reviews lower HDL values and higher LDL cholesterol and serum triglycerides. Compared to controls, HIV-infected patients had lower peak diastolic strain rate and higher myocardial mass (34) .
The prevalence of systolic dysfunction has decreased in developed countries. Due to a n t i re t ro v i r a l t h e r a p y , t h e d i a s t o l i c dysfunction is now dominant. The exact impact of diastolic dysfunction is unknown.
Further studies are needed to determine the prognosis of these patients. The HIV-infected patients can have asymptomatic myocardial imaging abnormalities, which do not correlate with the stage of the infectious disease and can be a risk factor to major cardiac events.
Symptomatic cardiomyopathy
The first case of dilated cardiomyopathy in a HIV infected patient was described in
1986 .The incidence of symptomatic (35) cardiomyopathy associated with HIV infection new cases is 1 to 2, and the prevalence was reported in approximately 4-10% . Dilated cardiomyopathy appears late (36) and it is often associated with the stage of the infectious disease.
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